GSK Flixotide Nebules approved in China as a new option for the treatment of childhood asthma

GSK announced today that its Flixotide Nebules (generic name: Fluticasone Propionate Nebuliser Suspension) has been approved by the China Food and Drug Administration (CFDA), for the treatment of mild to moderate asthma acute exacerbations in children and adolescents aged 4 – 16 years. 

Flixotide Nebules can significantly improve lung function and relieve acute symptoms through continuous strong anti-inflammatory effect. 

Dr. Wim Swyzen, VP and Country Medical Director for GSK China said: “It’s medically important and critical to prevent and adequately manage asthma and exacerbations in children. The approval of Flixotide Nebules provides an important option to help relieve acute symptoms for Chinese children with asthma and effectively reduce application of systemic corticosteriods.” 

According to the Third Epidemiological Survey of Urban Childhood Asthma in China published in 2013, about two-thirds of asthma children in China had experienced asthma episodes over the past 12 months, among whom 16.2 per cent had been hospitalised.1 

Flixotide has been launched in China since 2000. Following the approval of a new indication of Flixotide Aerosol for asthma prevention therapy for children aged 1-4 years last year, another dosage form of Flixotide, Flixotide Nebules, has now been approved in China. 

“We are committed to helping Chinese respiratory patients improve their condition and quality of life. We are working on and committed to bringing more innovative and advanced medicines and solutions in the future to provide individualised treatment for patients with chronic airway diseases  in China,” Wim said.

 

 

As part of the ‘in China, with China, for China’ strategy, GSK China has:

  • Announced partnership with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience in Aug 2017.
  • Announced innovative antiretroviral Single Tablet Regimen Triumeq received approval in China in Aug 2017.
  • Announced Cervarix, first vaccine for cervical cancer prevention in mainland China, was officially launched in July 2017.
  • Announced the collaboration programme to aid hepatitis prevention and treatment in poverty-stricken areas of the western region in July 2017.
  • Announced Seroxat CR and Tykerb on the list of reimbursed drugs as results of the national health insurance negotiations in July 2017.
  • Announced a strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases in June 2017.
  • Aided the National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention that officially kicked off in June 2017.
  • Announced Viread, Arixtra, Requip and Mivacron included in the “2017 National Reimbursement Drug List” in Mar 2017.
  • Joined hands with the Home of Red Ribbon to combat HIV/AIDS, unveiling plan to support people living with HIV in Nov 2016.
  • Announced the strategic partnership with China Preventive Medicine Association (CPMA) to address major public health challenges in China in Nov 2016.
  • Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016.
  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Formalised a partnership with Shanghai-based Desano Pharmaceuticals to locally manufacture the Active Pharmaceutical Ingredient for Tivicay (dolutegravir) in July 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.

 

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

 

GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.

 

GSK enquiries:

Susan Song            susan.s.song@gsk.com      (China)

 

References:

  1. National pediatric asthma collaborative group. Third epidemiological survey of urban childhood asthma in China. Chinese Journal of Pediatrics, 2013:51:729-737